-2.17 %
-2.17 %
-9.80 %
-75.57 %
-75.10 %
-79.15 %
-82.99 %
-88.31 %
-85.11 %
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read moreMarket cap
113.26M EUR
Turnover
196.21K EUR
P/E (adj.) (26e)
-4.81
EV/EBIT (adj.) (26e)
-5.55
P/B (26e)
86.25
EV/S (26e)
26,375.89
Dividend yield-% (26e)
-
